Also found in: Encyclopedia, Wikipedia.
AMRIAlbany Molecular Research (stock symbol)
AMRIAdvanced Manufacturing Research Institute (Japan)
AMRIAmerican Medical Research Institute (Saint Petersburg, FL)
AMRIAnterior Medial Rotary Instability (orthopedics)
AMRIAdvanced Magnetic Research Institute (Mocksville, NC)
AMRIAdvanced Materials Research Institute
AMRIAdult Movie Review Index
AMRIAgricultural Mechanization Research Institute (Faisalabad, Pakistan)
AMRIAssociate Member of the Royal Institution (UK)
References in periodicals archive ?
On behalf of Lauro 57 and its investors, we couldn't be more pleased to be joining AMRI," said Clessidra Chief Executive Officer, Maurizio Bottinelli.
This is another example of the AMRI SMART-SOURCING strategy of creating partnerships to deliver better outcomes to our customers.
AMRI said, aggregate consideration for the contract is $54 million and more $2 million in stakes of AMRI common stock if Whitehouse Labs mounts certain benchmarks for the year.
Under the ten yer agreement, AMRI will revceive funding of up to USD37.
Prior to AMRI, he was a director at Dishman Japan Ltd, responsible for sales and business development activities.
For this transaction, total cash consideration is of $54 million, and an additional $2 million in shares of AMRI common stock contingent upon Whitehouse Labs achieving certain 2015 targets.
Further deploying its fully integrated drug discovery services model, AMRI will apply a complete menu of integrated biology and chemistry capabilities including assay development, screening, library production, hit identification, ADMET, computer-aided drug discovery (CADD), and medicinal chemistry.
The DMFP will see AMRI completing manufacturing, documentation, formulation, fill and finish, packaging, and labeling required for BPN compounds.
OsoBio is recognized as a premier contract manufacturer of highly complex injectable drug products and their expertise in large-scale commercial production is highly complementary to AMRI s early stage drug product manufacturing capabilities.
According to Dr Thomas E D'Ambra, chairman, president and CEO of AMRI, the partnership lays the groundwork for AMRI to be considered by Shire for future development and manufacturing opportunities.
This is the sixth milestone payment originating from a 2005 agreement in which AMRI licensed to Bristol-Myers Squibb its technology around central nervous system (CNS) triple reuptake transporter inhibitors as potential improved treatments for depression and diseases of the CNS.
AMRI said that Cedarburg is likely to continue to operate autonomously within AMRI s API business unit.